[HTML][HTML] Harnessing natural killer cells in non-small cell lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide. There are two main
subtypes: small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC). NSCLC …
subtypes: small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC). NSCLC …
[HTML][HTML] Recruited and tissue-resident natural killer cells in the lung during infection and cancer
M Franklin, E Connolly, T Hussell - Frontiers in Immunology, 2022 - frontiersin.org
Natural killer (NK) cells are an important component of the innate immune system, and have
a key role in host defense against infection and in tumor surveillance. Tumors and viruses …
a key role in host defense against infection and in tumor surveillance. Tumors and viruses …
Platinum‐Based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive Microenvironment
T Yang, S Zhang, H Yuan, Y Wang… - Angewandte Chemie …, 2023 - Wiley Online Library
Triggering receptor expressed on myeloid cells‐2 (TREM2) is a key pro‐tumorigenic marker
of tumor‐infiltrating macrophages, showing potent immunosuppressive activity in tumor …
of tumor‐infiltrating macrophages, showing potent immunosuppressive activity in tumor …
[HTML][HTML] CAR-T cells/-NK cells in cancer immunotherapy and the potential of MSC to enhance its efficacy: A review
The chimeric antigen receptor (CAR) plays a dynamic role in targeting tumour-associated
antigens in cancer cells. This novel therapeutic discovery combines fragments of …
antigens in cancer cells. This novel therapeutic discovery combines fragments of …
[HTML][HTML] Hsp70, in combination with IL-15 and PD-1 blocker, interferes with the induction of cytotoxic NK cells in relapsed acute myeloid leukemia patients
Objective: Natural killer (NK) cells are critical immune cells for acute myeloid leukemia
(AML) targeting. However, little is known about the relationship between using checkpoint …
(AML) targeting. However, little is known about the relationship between using checkpoint …
[HTML][HTML] BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3
F Reggiani, G Talarico, G Gobbi, E Sauta… - Nature …, 2024 - nature.com
Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the
pioneer tumors in which immunotherapy has radically changed patients' outcomes …
pioneer tumors in which immunotherapy has radically changed patients' outcomes …
Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung …
L Huang, N Lou, T Xie, L Tang, X Han, Y Shi - Cancer Immunology …, 2023 - Springer
Background Antigen-presenting cells (APC)/T/NK cells are key immune cells that play
crucial roles in fighting against malignancies including lung adenocarcinoma (LUAD). In this …
crucial roles in fighting against malignancies including lung adenocarcinoma (LUAD). In this …
[HTML][HTML] Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase …
MG Choi, GW Son, MY Choi, JS Jung… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background Choosing treatments for epidermal growth factor receptor (EGFR)-mutated non-
small cell lung cancer (NSCLC) patients with osimertinib resistance is challenging. We …
small cell lung cancer (NSCLC) patients with osimertinib resistance is challenging. We …
GABRP is a promising prognostic biomarker and associated with immune cell infiltration in lung squamous cell carcinoma
J Fu, J Lin, X Zeng, G Li, Y Wei… - … and Personalized Medicine, 2023 - Taylor & Francis
Background GABRP has been reported to play an oncogenic role in various carcinomas.
However, no report has been found for its involvement in lung squamous cell carcinoma …
However, no report has been found for its involvement in lung squamous cell carcinoma …
[HTML][HTML] A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer
P Yao, S Liang, Z Liu, C Xu - Frontiers in Immunology, 2024 - frontiersin.org
Lung cancer (LC) produces some of the most malignant tumors in the world, with high
morbidity and mortality. Tumor immune microenvironment (TIME), a component of the tumor …
morbidity and mortality. Tumor immune microenvironment (TIME), a component of the tumor …